🇺🇸 FDA
Patent

US 10844040

Nrf2 activating compounds and uses thereof

granted A61PA61P17/06A61P25/00

Quick answer

US patent 10844040 (Nrf2 activating compounds and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P17/06, A61P25/00, A61P29/00, A61P37/00